Aspirin and pancreatic cancer
This article was originally published in The Tan Sheet
Executive Summary
Researchers estimate "43% of pancreatic cancer cases among nonusers of aspirin might be prevented by aspirin use," according to prospective study appearing in Aug. 7 Journal of the National Cancer Institute. Kristen Anderson, PhD, University of Minnesota, et al., followed 28,283 post-menopausal women from the Iowa Women's Health Study between 1992-1999, identifying 80 cases of pancreatic cancer. Researchers observed "a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week," finding a 61% reduced risk when aspirin was used at least six times per week. Data "indicate that aspirin might be chemopreventive for pancreatic cancer," Anderson et al. say, although they recommend further studies "with detailed assessments of dose, duration and drug type used"...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.